Owkin, Genmab A/S to explore cancer patient profiles for treatment improvements
Today, Owkin announced a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases, to better understand the complex biological profiles of cancer patients.
Owkin will apply state-of-the-art machine learning to multimodal patient data, accessed through their federated research network of leading academic centers and medical experts to improve patient outcomes by analysing certain patient subgroups’ response to treatments in an effort to evaluate the medical impact of Genmab’s clinical assets, including trial design and patient selection.
The research agreement will focus on patients diagnosed with certain types of cancers.
Financial terms are not disclosed but include an upfront payment and R&D funding.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
